March 1st 2023
Sarilumab is a fully human monoclonal antibody indicated for patients with polymyalgia rheumatica who had an inadequate response to corticosteroids or are unable to tolerate corticosteroid taper.
Clinical Overview: Cyletzo, a Biosimilar Version of Adalimumab
July 19th 2022Indications for adalimumab include ankylosing spondylitis, Crohn disease, chronic plaque psoriasis, juvenile idiopathic arthritis, moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Read More
FDA Approves New Indication for Rituximab Biosimilar for Rheumatoid Arthritis
June 7th 2022In addition to the new approval for rheumatoid arthritis, Riabni has already been approved for the treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis.
Read More
Daily Medication Pearl: Upadacitinib (Rinvoq)
March 4th 2022Upadacitinib (Rinvoq) is a Janus kinase (JAK) inhibitor being investigated to treat rheumatoid arthritis, Crohn disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA giant cell arteritis, and Takayasu arteritis
Read More
FDA Approves Abatacept With Calcineurin Inhibitor for Prophylaxis of Acute Graft Versus Host Disease
December 17th 2021Abatacept is also approved for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, and moderate to severe polyarticular juvenile idiopathic arthritis for children 2 years of age and older.
Read More
Study: Certain Immunosuppressing Drugs Do Not Increase Risk for Contracting COVID-19
September 23rd 2020A recent study found that patients on immunosuppressive therapy for common skin and rheumatic diseases, such as psoriasis and rheumatoid arthritis, are not at an increased risk for contracting COVID-19.
Read More